Prevention of Immunotoxin-Induced Immunogenicity by Coadministration with CTLA4Ig Enhances Antitumor Efficacy

Journal of Immunology

Volumn 159, Issue 10, 1997, Pages 5168-5173

  Siegall, Clay B ^a,b   Haggerty, Helen G ^a   Warner, Garvin L ^a   Chace, Dana ^a   Mixan, Bruce ^a   Linsley, Peter S ^b   Davidson, Thomas ^a  

^a BRISTOL MYERS SQUIBB COMPANY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIBODY CONJUGATE; ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; BR96 SFV PE40; BR96 SFV-PE40; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; BROWN NORWAY RAT; CARCINOMA; COLON TUMOR; DOG; FEMALE; HUMAN; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MOUSE; RAT; WISTAR FURTH RAT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; CARCINOMA; COLONIC NEOPLASMS; DOGS; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTOXINS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED BALB C; RATS; RATS, INBRED BN; RATS, INBRED WF; RECOMBINANT FUSION PROTEINS;

EID: 0031573069     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Siegall, C. B., D. Chace, B. Mixan, U. Garrigues, H. Wan, L. Paul, I. Hellström, and K. E. Hellström. 1994. In vitro and in vivo characterization of BR96 sFv-PE40, a single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats. J. Immunol. 152:2377.
2. Hellström, I., K. E. Hellström, C. B. Siegall, and P. A. Trail. 1995. Immunoconjugates and immunotoxins for therapy of carcinomas. Adv. Pharmacol. 33:349.
3. Vitetta, E. S., M. Stone, P. Amlot, J. Fay, R. May, M. Till, J. Newman, P. Clark, R. Collins, D. Cunningham, V. Ghetie, J. W. Uhr, and P. E. Thore. 1991. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 51:4052.
4. Amlot, P. L., M. J. Stone, D. Cunningham, J. Fay, J. Newman, R. Collins, R. May, M. McCarthy, J. Richardson, V. Ghetie, O. Ramilo, P. E. Thorpe, J. W. Uhr, and E. S. Vitetta. 1993. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82:2624.
5. Sausville, E. A., D. Headlee, M. Stetler-Stevenson, E. S. Jaffe, D. Solomon, W. D. Figg, J. Herdt, W. C. Kopp, H. Rager, S. M. Steinberg, V. Ghetie, J. Schindler, J. Uhr, R. E. Wittes, and E. S. Vitetta. 1995. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood 85:3457.
6. Stone M. J., E. A. Sausville, J. W. Fay, D. Headlee, R. H. Collins, W. D. Figg, M. Stetler-Stevenson, V. Jain, E. S. Jaffe, D. Solomon, R. M. Lush, A. Senderowicz, V. Ghetie, J. Schindler, J. W. Uhr, and E. S. Vitetta. 1996. A phase 1 study of bolus versus continuous infusion of the anti-CD19 immunotoxin. IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88:1188.
7. Pai, L. H., R. Wittes, A. Setser, M. C. Willingham, and I. Pastan. 1996. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat. Med. 2:350.
8. Conroy, R. M., M. B. Khazaeli, M. N. Saleh, V. Ghetie, E. S. Vitetta, T. Liu, and A. F. LoBuglio 1996. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration. J. Immunother. 18:231.
9. Lynch, T. J., Jr., J. M. Lambert, F. Coral, J. Shefner, P. Wen, W. A. Blattler, A. R. Collinson, P. D. Arineillo, G. Braman, S. Cook, D. Esselstine, A. Elias, A. Sharkin, and J. Ritz. 1997. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J. Clin. Oncol. 15:723.
10. Engert, A., V. Diehl, R. Schnell, A. Radszuhn, M.-T. Hatwig, S. Drillich, G. Schön, H. Bohlen, H. Tesch, M.-L. Hansmann, S. Barth, J. Schindler, V. Ghetie, J. Uhr, and E. S. Vitetta. 1997. A phase-I study of an anti-CD25 ricin A chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymshy; phoma. Blood 2:403.
11. Ledermann, J. A., R. H. Begent, K. D. Bagshawe, S. J. Riggs, F. Searle, M. G. Glaser, A. J. Green, and R. G. Dale. 1988a. Repeated antitumour antibody therapy in man with suppression of the host response with cyclosporin A. Br. J. Cancer 58:654.
12. Ledermann, J. A., R. H. Begent, and K. D. Bagshawe. 1988b. CyclospormA prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits. Br. J. Cancer 58:562.
13. Selvaggi, K., E. A. Saria, R. Schwartz, D. R. Vlock, S. Ackerman, N. Wedel, J. M. Kirkwood, H. Jones, and M. S. Ernstoff. 1993. Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J. Immunother. 13:201.
14. Oratz, R., J. L. Speyer, J. C. Wernz, H. Hochster, M. Meyers, R. Mischak, and L. E. Spitler. 1990 Anti-melanoma monoclonal antibody ricin A chain immunoconjugate (XMMME001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase I trial. J. Biol. Response Modif. 9:345.
15. Lenschow, D. J., Y. Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G. Gibson, P. S. Linsley, and J. S. Bluestone. 1992. Long-term survival of xenogenic pancreatic islet grafts induced by CTLA4Ig. Science 257:789.
16. Linsley P. S., P. M. Wallace, J. Johnson, M. G. Gibson, J. L. Greene, J. A. Ledbetter, C. Singh, and M. A. Tepper. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257:792.
17. Lebwohl, M., S. Kang, C. Guzzo, B. Jegasothy, M. Goldfarb, R. Mann, B. Goffe, A. Menter, N. Lowe, G. Krueger, M. Brown, R. Weiner, M. Birkhofer, G. Warner, K. Berry, P. Linsley, J. Krueger, H. Ochs, S. Kelley, and J. Abrams. 1997. CTLA4Ig (BMS-188667)-mediated blockade of T cell costimulation in patients with psoriasis vulgaris. J. Invest. Dermatol. 108:570.
18. Shyu, W. C., N. Srinivas, R. S. Weiner, C. Gleason, G. Warner, L. K. Tay, D. S. Greene, and R. H. Barhaiya. 1996. Pharmacokinetics of intravenous CTLA4Ig (BMS-188667) in cynomolgus monkeys following single and multiple doses. Pharmacol. Sci. 2:1.
19. Hellström, K. E., D. E. Yelton, H. P. Fell, D. Beaton, M. Gayle, M. MacLean, M. Kahn, and I. Hellström. 1990. Epitope mapping and use of anti-idiotypic antibodies to the L6 monoclonal anticarcinoma antibody. Cancer Res. 50:2449.
20. Turka, L. A., P. S. Linsley, H. Lin, W. Brady, J. M. Leiden, R. Wei, M. L. Gibson, X. Zheng, S. Myrdal, D. Gordon, T. Bailey, S. F. Bolling, and C. B. Thompson. 1992. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. USA 89:11102.
21. Foy, T. M., D. M. Sheperd, F. H. Durie, A. Aruffo, J. A. Ledbetter, and R. J. Noelle. 1993. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J. Exp. Med. 178:1567.
22. Clark, L. B., T. M. Foy, and R. J. Noelle. 1996. CD40 and its ligand. Adv. Immunol. 63:43.